Literature DB >> 8772403

A review of the treatment and survival rates of 138 patients with glioblastoma multiforme.

S J Jubelirer1.   

Abstract

This article reviews the cases of 138 patients at the Charleston Area Medical Center who were treated for glioblastoma multiforme (astrocytoma Grade IV) between 1966-1987. Data was obtained from the hospital's tumor registry, inpatient/outpatient records, pathology reports, as well as radiotherapy records. The median survival rate for all patients was 7 months (range 1-36 months). The median survival of the patients who underwent complete resection and received radiotherapy was 12 months, while the median survival rate was four months for patients who had complete resection but did not undergo radiotherapy. In addition, the median survival of the patients who underwent incomplete resection with radiotherapy was 10 months compared to a survival rate of 3 months of those who did not undergo radiotherapy after incomplete resection. Radiotherapy was the most significant predictor of survival with age being the major factor. Despite the clinical advancements made in the past 10-15 years, no impact has yet been achieved on the natural history of glioblastoma multiforme.

Entities:  

Mesh:

Year:  1996        PMID: 8772403

Source DB:  PubMed          Journal:  W V Med J        ISSN: 0043-3284


  3 in total

1.  Considering iatrogenic psychosis after malignant glioma resection.

Authors:  Ashish Harish Shah; Catherine E Gordon; Amade Bregy; Nirav Shah; Ricardo Jorge Komotar
Journal:  BMJ Case Rep       Date:  2014-04-23

2.  Anticancer activity of β-Elemene and its synthetic analogs in human malignant brain tumor cells.

Authors:  Qingdi Quentin Li; Rebecca X Lee; Huasheng Liang; Yuhua Zhong
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

3.  Glioblastoma Survival Outcomes at a Tertiary Hospital in Appalachia: Factors Impacting the Survival of Patients Following Implementation of the Stupp Protocol.

Authors:  Ogaga Urhie; Ryan Turner; Brandon Lucke-Wold; Walid Radwan; Janice Ahn; Kymberly Gyure; Sanjay Bhatia
Journal:  World Neurosurg       Date:  2018-04-06       Impact factor: 2.104

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.